Last reviewed · How we verify
RV001V
At a glance
| Generic name | RV001V |
|---|---|
| Sponsor | RhoVac APS |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME) (PHASE1)
- Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease (PHASE2)
- Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (PHASE2)
- RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |